National Vaccine
Information Center

Your Health. Your Family. Your Choice.

MedAlerts Home
Search Results

From the 10/15/2021 release of VAERS data:

Found 4 cases where Age is 12-or-more-and-under-18 and Vaccine is COVID19 and Manufacturer is MODERNA and Symptom is Cerebral venous sinus thrombosis or Cerebral venous thrombosis or Coagulopathy or Deep vein thrombosis or Disseminated intravascular coagulation or Embolism or Idiopathic thrombocytopenic purpura or Immune thrombocytopenia or Immune thrombocytopenic purpura or Ischaemic stroke or Myocardial infarction or Petechiae or Pulmonary embolism or Purpura or Thrombocytopenia or Thrombosis or Vasculitis

Table

   
AgeCountPercent
12-17 Years125%
17-44 Years375%
TOTAL4100%



Case Details

VAERS ID: 1396865 (history)  
Form: Version 2.0  
Age: 17.0  
Sex: Male  
Location: Foreign  
Vaccinated:2021-04-02
Onset:2021-04-02
   Days after vaccination:0
Submitted: 0000-00-00
Entered: 2021-06-14
Vaccin­ation / Manu­facturer Lot / Dose Site / Route
COVID19: COVID19 (COVID19 (MODERNA)) / MODERNA 3000495 / UNK - / OT

Administered by: Unknown       Purchased by: ?
Symptoms: Headache, Paraesthesia, Product administered to patient of inappropriate age, Thrombosis
SMQs:, Peripheral neuropathy (broad), Embolic and thrombotic events, vessel type unspecified and mixed arterial and venous (narrow), Thrombophlebitis (broad), Guillain-Barre syndrome (broad), Medication errors (narrow)

Life Threatening? No
Birth Defect? No
Died? No
Permanent Disability? No
Recovered? Yes
Office Visit? No
ER Visit? No
ER or Doctor Visit? No
Hospitalized? No
Previous Vaccinations:
Other Medications:
Current Illness:
Preexisting Conditions:
Allergies:
Diagnostic Lab Data:
CDC Split Type: DEMODERNATX, INC.MOD20212

Write-up: Thrombosis; Paraesthesia; Headache; Inappropriate age at vaccine administration; This regulatory authority case was reported by a consumer and describes the occurrence of THROMBOSIS (Thrombosis), PARAESTHESIA (Paraesthesia) and HEADACHE (Headache) in a 17-year-old male patient who received mRNA-1273 (COVID 19 Vaccine Moderna) (batch no. 3000495) for COVID-19 vaccination. The occurrence of additional non-serious events is detailed below. No Medical History information was reported. On 02-Apr-2021, the patient received dose of mRNA-1273 (COVID 19 Vaccine Moderna) (unknown route) unknown. On 02-Apr-2021, the patient experienced THROMBOSIS (Thrombosis) (seriousness criteria hospitalization prolonged and medically significant), PARAESTHESIA (Paraesthesia) (seriousness criterion hospitalization prolonged), HEADACHE (Headache) (seriousness criterion hospitalization prolonged) and PRODUCT ADMINISTERED TO PATIENT OF INAPPROPRIATE AGE (Inappropriate age at vaccine administration). At the time of the report, THROMBOSIS (Thrombosis), PARAESTHESIA (Paraesthesia) and HEADACHE (Headache) had resolved and PRODUCT ADMINISTERED TO PATIENT OF INAPPROPRIATE AGE (Inappropriate age at vaccine administration) outcome was unknown. The action taken with mRNA-1273 (COVID 19 Vaccine Moderna) (Unknown) was unknown. Concomitant medication use was not provided. No Treatment information was provided. Based on the current available information and temporal association between the use of the product and the thrombosis, headache and paresthesia, a causal relationship cannot be excluded. Event terms, onset dates and outcomes captured per SD Authority reporting. Event added tp reflect that the patient was below age specified in label. Events seriousness per assessment by Authority and per IME list; Sender''s Comments: Based on the current available information and temporal association between the use of the product and the thrombosis, headache and paresthesia, a causal relationship cannot be excluded. Event terms, onset dates and outcomes captured per SD Authority reporting. Event added tp reflect that the patient was below age specified in label. Events seriousness per assessment by Authority and per IME list


VAERS ID: 1629367 (history)  
Form: Version 2.0  
Age: 17.0  
Sex: Male  
Location: Foreign  
Vaccinated:2021-07-24
Onset:2021-07-24
   Days after vaccination:0
Submitted: 0000-00-00
Entered: 2021-08-24
Vaccin­ation / Manu­facturer Lot / Dose Site / Route
COVID19: COVID19 (COVID19 (MODERNA)) / MODERNA 3004672 / 1 - / OT

Administered by: Unknown       Purchased by: ?
Symptoms: Alanine aminotransferase increased, Aspartate aminotransferase increased, Asthenia, Blood lactate dehydrogenase, Hypertransaminasaemia, Lymphadenopathy, Lymphocyte count, Lymphocytosis, Platelet count, Pyrexia, SARS-CoV-2 test, Thrombocytopenia
SMQs:, Liver related investigations, signs and symptoms (narrow), Haematopoietic thrombocytopenia (narrow), Neuroleptic malignant syndrome (broad), Systemic lupus erythematosus (broad), Anticholinergic syndrome (broad), Guillain-Barre syndrome (broad), Drug reaction with eosinophilia and systemic symptoms syndrome (narrow), COVID-19 (broad)

Life Threatening? No
Birth Defect? No
Died? No
Permanent Disability? No
Recovered? No
Office Visit? No
ER Visit? No
ER or Doctor Visit? No
Hospitalized? No
Previous Vaccinations:
Other Medications:
Current Illness: Irritable bowel
Preexisting Conditions:
Allergies:
Diagnostic Lab Data: Test Date: 20210804; Test Name: ALT high; Result Unstructured Data: 536 U/L; Test Date: 20210804; Test Name: AST high; Result Unstructured Data: 325 U/L; Test Date: 20210730; Test Name: LDH; Result Unstructured Data: 651 U/L; Test Date: 20210804; Test Name: Lymphocytes; Result Unstructured Data: 10340/mm3; Test Date: 20210730; Test Name: platelets; Result Unstructured Data: 101000/mm3; Test Date: 20210730; Test Name: COVID-19 PCR test; Test Result: Negative ; Result Unstructured Data: Negative
CDC Split Type: ESMODERNATX, INC.MOD20212

Write-up: Lymphocytosis; Hypertransaminasaemia; Thrombopenia; Asthenia; Fever; Lymphadenopathy cervical; This case was received (Reference number: ES-AEMPS-971123) on 16-Aug-2021 and was forwarded to Moderna on 16-Aug-2021. This regulatory authority case was reported by an other health care professional and describes the occurrence of THROMBOCYTOPENIA (Thrombopenia) in a 17-year-old male patient who received mRNA-1273 (batch no. 3004672) for COVID-19 vaccination. The occurrence of additional non-serious events is detailed below. Concurrent medical conditions included Irritable bowel. On 24-Jul-2021, the patient received first dose of mRNA-1273 (Intramuscular) 1 dosage form. On 24-Jul-2021, the patient experienced ASTHENIA (Asthenia), PYREXIA (Fever) and LYMPHADENOPATHY (Lymphadenopathy cervical). On 30-Jul-2021, the patient experienced THROMBOCYTOPENIA (Thrombopenia) (seriousness criterion medically significant), LYMPHOCYTOSIS (Lymphocytosis) and HYPERTRANSAMINASAEMIA (Hypertransaminasaemia). At the time of the report, THROMBOCYTOPENIA (Thrombopenia), ASTHENIA (Asthenia), LYMPHOCYTOSIS (Lymphocytosis), HYPERTRANSAMINASAEMIA (Hypertransaminasaemia), PYREXIA (Fever) and LYMPHADENOPATHY (Lymphadenopathy cervical) was resolving. DIAGNOSTIC RESULTS (normal ranges are provided in parenthesis if available): On 30-Jul-2021, Blood lactate dehydrogenase: 651 U/L (High) 651 U/L. On 30-Jul-2021, Platelet count: 101000 (abnormal) 101000/mm3. On 30-Jul-2021, SARS-CoV-2 test: negative (Negative) Negative. On 04-Aug-2021, Alanine aminotransferase increased: 536 U/L (High) 536 U/L. On 04-Aug-2021, Aspartate aminotransferase increased: 325 U/L (High) 325 U/L. On 04-Aug-2021, Lymphocyte count: 10340 (High) 10340/mm3. For mRNA-1273 (Intramuscular), the reporter did not provide any causality assessments. Concomitant product was not provided by the reporter. Treatment information was not provided. Action taken with mRNA 1273 in response to event was not applicable. Based on the current available information and temporal association between the use of the product and the start date of the events, a causal relationship cannot be excluded.; Sender''s Comments: Based on the current available information and temporal association between the use of the product and the start date of the events, a causal relationship cannot be excluded.


VAERS ID: 1690755 (history)  
Form: Version 2.0  
Age: 17.0  
Sex: Female  
Location: Foreign  
Vaccinated:2021-08-09
Onset:2021-08-11
   Days after vaccination:2
Submitted: 0000-00-00
Entered: 2021-09-11
Vaccin­ation / Manu­facturer Lot / Dose Site / Route
COVID19: COVID19 (COVID19 (MODERNA)) / MODERNA 214041 / 1 - / OT

Administered by: Unknown       Purchased by: ?
Symptoms: Haemoglobin, Platelet count, Thrombocytopenia
SMQs:, Haematopoietic thrombocytopenia (narrow), Systemic lupus erythematosus (broad), Drug reaction with eosinophilia and systemic symptoms syndrome (broad)

Life Threatening? No
Birth Defect? No
Died? No
Permanent Disability? No
Recovered? No
Office Visit? No
ER Visit? No
ER or Doctor Visit? No
Hospitalized? Yes, ? days
   Extended hospital stay? No
Previous Vaccinations:
Other Medications:
Current Illness:
Preexisting Conditions:
Allergies:
Diagnostic Lab Data: Test Date: 20210811; Test Name: Haemoglobin; Result Unstructured Data: 7,8 dosage form; Test Date: 20210811; Test Name: Platelet count; Result Unstructured Data: 87000
CDC Split Type: ITMODERNATX, INC.MOD20213

Write-up: Piastrinopenia transitoria verosimilmente post-vaccinale; This case was received via (Reference number: 776251) on 02-Sep-2021 and was forwarded to Moderna on 02-Sep-2021. This regulatory authority case was reported by a physician and describes the occurrence of THROMBOCYTOPENIA (Piastrinopenia transitoria verosimilmente post-vaccinale) in a 17-year-old female patient who received mRNA-1273 (Spikevax) (batch no. 214041) for COVID-19 vaccination. No Medical History information was reported. On 09-Aug-2021, the patient received first dose of mRNA-1273 (Spikevax) (Intramuscular) 1 dosage form. On 11-Aug-2021, after starting mRNA-1273 (Spikevax), the patient experienced THROMBOCYTOPENIA (Piastrinopenia transitoria verosimilmente post-vaccinale) (seriousness criteria hospitalization and medically significant). At the time of the report, THROMBOCYTOPENIA (Piastrinopenia transitoria verosimilmente post-vaccinale) was resolving. DIAGNOSTIC RESULTS (normal ranges are provided in parenthesis if available): On 11-Aug-2021, Haemoglobin: 7,8 (Low) 7,8 dosage form. On 11-Aug-2021, Platelet count: 87000 (Low) 87000. The action taken with mRNA-1273 (Spikevax) (Intramuscular) was unknown. For mRNA-1273 (Spikevax) (Intramuscular), the reporter did not provide any causality assessments. The concomitant medications were not reported. The treatment information was not provided. Patient had transient thrombocytopenia, probably post vaccination. Company comment: Based on the current available information and temporal association between the use of the product and the start date of the event, a causal relationship cannot be excluded. Most recent FOLLOW-UP information incorporated above includes: On 02-Sep-2021: Translation received on 6 SEP 2021: Updated narrative with the verbatim reported by primary source. On 06-Sep-2021: Follow-up received on 06 SEP 2021 contains no new information.; Sender''s Comments: Based on the current available information and temporal association between the use of the product and the start date of the event, a causal relationship cannot be excluded.


VAERS ID: 1763554 (history)  
Form: Version 2.0  
Age: 15.0  
Sex: Female  
Location: Foreign  
Vaccinated:2021-09-07
Onset:2021-09-16
   Days after vaccination:9
Submitted: 0000-00-00
Entered: 2021-10-06
Vaccin­ation / Manu­facturer Lot / Dose Site / Route
COVID19: COVID19 (COVID19 (MODERNA)) / MODERNA 3005293 / 1 - / OT

Administered by: Unknown       Purchased by: ?
Symptoms: Blood test, Chest X-ray, Computerised tomogram, Fibrin D dimer, Magnetic resonance imaging, Platelet count, SARS-CoV-2 test, Thrombocytopenia, Thrombosis, Ultrasound scan
SMQs:, Haematopoietic thrombocytopenia (narrow), Systemic lupus erythematosus (broad), Embolic and thrombotic events, vessel type unspecified and mixed arterial and venous (narrow), Thrombophlebitis (broad), Drug reaction with eosinophilia and systemic symptoms syndrome (broad), COVID-19 (broad)

Life Threatening? No
Birth Defect? No
Died? No
Permanent Disability? Yes
Recovered? No
Office Visit? No
ER Visit? No
ER or Doctor Visit? No
Hospitalized? Yes, ? days
   Extended hospital stay? No
Previous Vaccinations:
Other Medications:
Current Illness:
Preexisting Conditions:
Allergies:
Diagnostic Lab Data: Test Date: 20210921; Test Name: Blood test; Result Unstructured Data: No aggregation findings in smear.; Test Date: 20210922; Test Name: Blood test; Test Result: Positive ; Result Unstructured Data: Anti-HIT antibody (test method: latex agglutination): Positive 1.6 U/mL; Test Date: 20210921; Test Name: Chest X-ray examination; Result Unstructured Data: Findings of thrombosis and embolism: None; Test Date: 20210920; Test Name: CT Scan; Result Unstructured Data: showed occlusion of the right transverse venous sinus, venous infarction in the right temporal occipital lobe, and hemorrhagic infarction; Test Date: 20210921; Test Name: CT Scan; Result Unstructured Data: No imaging Imaging site: Head Findings: Hemorrhagic infarction; Test Date: 20210924; Test Name: CT Scan; Result Unstructured Data: With imaging Imaging site: Head to lower extremities Findings: Right transverse sinus thrombus and pulmonary artery thrombosis; Test Date: 20210921; Test Name: D-dimer; Result Unstructured Data: 18.5 mcg/mL; Test Date: 20210920; Test Name: MRI; Result Unstructured Data: showed occlusion of the right transverse venous sinus, venous infarction in the right temporal occipital lobe, and hemorrhagic infarction; Test Date: 20210921; Test Name: MRI; Result Unstructured Data: No imaging, Imaging site: Head Findings of thrombosis and embolism: Suspected Findings: Sigmoid venous sinus occlusion in the right transverse sinus; Test Date: 20210921; Test Name: Plt; Result Unstructured Data: 130,000/mcL; Test Date: 20210924; Test Name: SARS-CoV-2 test; Test Result: Negative ; Result Unstructured Data: Negative; Test Date: 20210921; Test Name: Echography; Result Unstructured Data: Imaging site: Heart Findings of thrombosis and embolism: None No abnormality in the echography.
CDC Split Type: JPMODERNATX, INC.MOD20213

Write-up: Thrombosis with thrombocytopenia; Thrombosis with thrombocytopenia; This case was received via regulatory authority (Reference number: JP-TAKEDA-2021TJP098758) on 27-Sep-2021 and was forwarded to Moderna on 01-Oct-2021. This case, initially reported to the regulatory authority by a (physician), was received via the regulatory authority (Ref, v21127721). The patient was born a premature baby and had mild intellectual disability, but no other abnormalities were noted including abnormal blood clotting. On 07-Sep-2021, the patient received the 1st dose of this vaccine. On 16-Sep-2021, the patient experienced vomiting. On 17-Sep-2021, the patient experienced headache. On 20-Sep-2021, the patient received detailed examinations, and simple CT and MRI (MRV) showed occlusion of the right transverse venous sinus, venous infarction in the right temporal occipital lobe, and hemorrhagic infarction. Venous infarction and haemorrhage due to venous sinus thrombosis were diagnosed. On 21-Sep-2021, the patient was hospitalized. Neurological symptoms were suspected to be left homonymous hemianopsia, and the patient was scheduled for detailed examinations by an ophthalmologist. Contrast-enhanced CT for systemic screening revealed suspected thrombus in the right transverse venous sinus and multiple thrombi in the lung. When the patient visited a hospital, blood collection showed Plt of 130,000/mcL and D-dimer of 18.5 mcg/mL. No other causes of clotting abnormality or history of heparin use were found in the various blood samples. Thrombosis with thrombocytopenia (TTS) was suspected, and it was confirmed that there was no increase in hemorrhage, and administration of argatroban hydrate was started. Headache tended to improve. Antiplatelet factor 4 antibody (latex agglutination) showed positive. On 26-Sep-2021, the symptoms were resolving. The measurement of antiplatelet factor 4 antibody with ELISA was planned to be requested to a university institution. The situation applied to all commonly stated criteria for TTS today. The outcome of thrombosis with thrombocytopenia was reported as resolving. (Blood test) (Date of test: 21-Sep-2021) Blood count: No aggregation findings in smear. (Echography) (Date of test: 21-Sep-2021) Imaging site: Heart Findings of thrombosis and embolism: None No abnormality in the echography. (CT scan) (Date of test: 21-Sep-2021) No imaging Imaging site: Head Findings: Hemorrhagic infarction (MRI examination) (Date of test: 21-Sep-2021) No imaging, Imaging site: Head Findings of thrombosis and embolism: Suspected Findings: Sigmoid venous sinus occlusion in the right transverse sinus (Chest X-ray examination) (Date of test: 21-Sep-2021) Findings of thrombosis and embolism: None (Blood test) (Date of test: 22-Sep-2021) Anti-HIT antibody (test method: latex agglutination): Positive 1.6 U/mL (CT scan) (Date of test: 24-Sep-2021) With imaging Imaging site: Head to lower extremities Findings: Right transverse sinus thrombus and pulmonary artery thrombosis (SARS-CoV-2 test) (Date of test: 24-Sep-2021) Nucleic acid amplification: Negative Follow-up investigation will be made. Company Comment: The events developed after the administration of COVID-19 vaccine mRNA (mRNA 1273) and there is temporal relationship.; Reporter''s Comments: Approximately 2 weeks after the vaccination, venous infarction due to venous sinus thrombosis, haemorrhage, and multiple thrombi in the pulmonary artery developed. Plt: 130,000/mcL, and D-dimer: 18.5 mcg/mL. Latex agglutination was made and tested positive for antiplatelet factor 4 antibody.; Sender''s Comments: This case concerns a 15-year-old female patient with no relevant medical history, who experienced serious AESI, unlisted event of Thrombocytopenia and thrombosis. The events occurred approximately 10 days after 1st dose of Moderna COVID-19 Vaccine. The rechallenge was unknown as the dose detail was not provided. The benefit-risk relationship of Moderna COVID-19 Vaccine is not affected by this report.


New Search

Link To This Search Result:

https://medalerts.org/vaersdb/findfield.php?TABLE=ON&GROUP1=AGE&EVENTS=ON&SYMPTOMS[]=Cerebral+venous+sinus+thrombosis+%2810083037%29&SYMPTOMS[]=Cerebral+venous+thrombosis+%2810008138%29&SYMPTOMS[]=Coagulopathy+%2810009802%29&SYMPTOMS[]=Deep+vein+thrombosis+%2810051055%29&SYMPTOMS[]=Disseminated+intravascular+coagulation+%2810013442%29&SYMPTOMS[]=Embolism+%2810061169%29&SYMPTOMS[]=Idiopathic+thrombocytopenic+purpura+%2810021245%29&SYMPTOMS[]=Immune+thrombocytopenia+%2810083842%29&SYMPTOMS[]=Immune+thrombocytopenic+purpura+%2810074667%29&SYMPTOMS[]=Ischaemic+stroke+%2810061256%29&SYMPTOMS[]=Myocardial+infarction+%2810028596%29&SYMPTOMS[]=Petechiae+%2810034754%29&SYMPTOMS[]=Pulmonary+embolism+%2810037377%29&SYMPTOMS[]=Purpura+%2810037549%29&SYMPTOMS[]=Thrombocytopenia+%2810043554%29&SYMPTOMS[]=Thrombosis+%2810043607%29&SYMPTOMS[]=Vasculitis+%2810047115%29&VAX=COVID19&VAXMAN=MODERNA&WhichAge=range&LOWAGE=12&HIGHAGE=18

Government Disclaimer on use of this data


Copyright © 2021 National Vaccine Information Center. All rights reserved.
21525 Ridgetop Circle, Suite 100, Sterling, VA 20166